<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426283</url>
  </required_header>
  <id_info>
    <org_study_id>06-10-07</org_study_id>
    <nct_id>NCT00426283</nct_id>
  </id_info>
  <brief_title>A Study of Flovent in Patients With Eosinophilic Esophagitis</brief_title>
  <official_title>A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marc Rothenberg, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects (both good and bad) of high dose swallowed&#xD;
      fluticasone propionate (Flovent) in subjects with eosinophilic esophagitis (EoE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Attained Remission.</measure>
    <time_frame>3 months</time_frame>
    <description>Remission is considered achieved when the highest eosinophil count per high power field (hpf) in all esophageal biopsies is &lt;/= 1 eosinophil/hpf after 3 months of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Decreased Cortisol Levels After 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Blood and saliva cortisol was measured and compared to reference range at 3 months. Participants with measures below the reference range were considered &quot;decreased&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Subject Age, Body Mass Index Z-score, and Allergic Status to Response to Flovent</measure>
    <time_frame>3 months</time_frame>
    <description>Strength of the association (odds ratio) of age, body mass index (BMI) z-score , and allergic status with response to Flovent. Allergic status is defined as a history of allergic disease (allergic rhinitis, hay fever, atopic dermatitis, eczema, food anaphylaxis, asthma, or positive skin prick tests). Response is defined as &lt;= 1 eosinophil/high power field in esophageal biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EoE Score After 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>The gene expression profile is associated with an EoE score algorithm reflecting disease status and severity in a quantifiable number - called the EoE score, based on a core set of 77 diagnostic genes. The EoE score was calculated for Flovent responders and placebo. Higher scores indicate normalization of genes associated with inflammation and fibrosis (disease severity). Therefore higher scores mean a better outcome. The minimum score is zero. There is no maximum score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Compliance With Therapy and Response to Flovent</measure>
    <time_frame>3 months</time_frame>
    <description>Odds ratio was determined to show the strength of the association between compliance with the drug therapy and response to the drug therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Abdominal Pain After Therapy</measure>
    <time_frame>3 months</time_frame>
    <description>Percent of participants responding that they experienced abdominal pain (i.e. they did not respond &quot;never&quot;) after therapy. Responses were dichotomized into &quot;Never&quot; and &quot;sometimes&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Flovent 1760 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone propionate 880 mcg twice daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent</intervention_name>
    <description>1760 mcg daily</description>
    <arm_group_label>Flovent 1760 mcg</arm_group_label>
    <other_name>Fluticasone propionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent for study by subject, or parent/guardian if subject is a&#xD;
             minor. Assent will be obtained from all minors 11 years of age and older.&#xD;
&#xD;
          -  Histological findings on esophageal biopsy to include peak eosinophil density â‰¥ 24 per&#xD;
             high power field (400x) in the proximal or distal esophagus validated by a pathologist&#xD;
             at CCHMC.&#xD;
&#xD;
          -  Allergy evaluation including skin-prick testing with multiple food antigens to ensure&#xD;
             elimination diet is not indicated.&#xD;
&#xD;
          -  Have undergone a minimum 3 months of elimination diet as indicated by skin-prick&#xD;
             testing without detectable resolution by repeat endoscopy with biopsies demonstrating&#xD;
             persistent EE OR subject/parental refusal to follow elimination diet. If the&#xD;
             subject/parent refuses the elimination diet, they are eligible for this study.&#xD;
&#xD;
          -  Treatment with a proton-pump inhibitor for at least two months (rounded to nearest&#xD;
             month) prior to endoscopy OR failure of histological improvement as defined by &lt; 1&#xD;
             eosinophil per HPF after 2 month (rounded to nearest month) trial of proton pump&#xD;
             inhibitor documented by prior endoscopy. The PPI must be used prior to endoscopy to&#xD;
             rule out the possibility of GERD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of poor tolerance to Fluticasone Propionate (FP), as defined as multiple&#xD;
             episodes of oral candidiasis, hypothalamic-pituitary-adrenal axis suppression as&#xD;
             evidenced by signs of Cushing syndrome, headaches, or increased respiratory infections&#xD;
             during exposure to Flovent&#xD;
&#xD;
          -  Unable to cooperate with use of MDI&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Concurrent or recent (within 3 months) use of systemic corticosteroids.&#xD;
&#xD;
          -  Unable to swallow medicines (i.e., fed only by gastrostomy tube).&#xD;
&#xD;
          -  Comorbid eosinophilic disorders.&#xD;
&#xD;
          -  Previously treated with swallowed glucocorticoid for EE within 3 months of the&#xD;
             screening visit. Nasal glucocorticoids taken for EE are permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc E. Rothenberg, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cchmc.org/cced</url>
    <description>Cincinnati Center for Eosinophilic Disorders</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <results_first_submitted>December 16, 2013</results_first_submitted>
  <results_first_submitted_qc>December 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2014</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Marc Rothenberg, MD</investigator_full_name>
    <investigator_title>Marc Rothenberg, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Eosinophilic Esophagitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flovent 1760 mcg</title>
          <description>Drug&#xD;
Flovent : 1760 mcg daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flovent 1760 mcg</title>
          <description>Drug&#xD;
Flovent : 880 mcg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.15" spread="6.42"/>
                    <measurement group_id="B2" value="13.54" spread="7.11"/>
                    <measurement group_id="B3" value="12.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Attained Remission.</title>
        <description>Remission is considered achieved when the highest eosinophil count per high power field (hpf) in all esophageal biopsies is &lt;/= 1 eosinophil/hpf after 3 months of therapy.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flovent 1760 mcg</title>
            <description>Drug&#xD;
Flovent : 880 mcg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Attained Remission.</title>
          <description>Remission is considered achieved when the highest eosinophil count per high power field (hpf) in all esophageal biopsies is &lt;/= 1 eosinophil/hpf after 3 months of therapy.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" lower_limit="44.9" upper_limit="81.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Decreased Cortisol Levels After 3 Months</title>
        <description>Blood and saliva cortisol was measured and compared to reference range at 3 months. Participants with measures below the reference range were considered &quot;decreased&quot;.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flovent 1760 mcg</title>
            <description>Fluticasone propionate 880 mcg twice daily for 3 months&#xD;
Flovent: 1760 mcg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Decreased Cortisol Levels After 3 Months</title>
          <description>Blood and saliva cortisol was measured and compared to reference range at 3 months. Participants with measures below the reference range were considered &quot;decreased&quot;.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Subject Age, Body Mass Index Z-score, and Allergic Status to Response to Flovent</title>
        <description>Strength of the association (odds ratio) of age, body mass index (BMI) z-score , and allergic status with response to Flovent. Allergic status is defined as a history of allergic disease (allergic rhinitis, hay fever, atopic dermatitis, eczema, food anaphylaxis, asthma, or positive skin prick tests). Response is defined as &lt;= 1 eosinophil/high power field in esophageal biopsies.</description>
        <time_frame>3 months</time_frame>
        <population>Analysis population is restricted only to those that were given Flovent for the purpose of determining whether these specific variables are associated with response to drug</population>
        <group_list>
          <group group_id="O1">
            <title>Flovent 1760 mcg</title>
            <description>Drug&#xD;
Flovent : 1760 mcg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Subject Age, Body Mass Index Z-score, and Allergic Status to Response to Flovent</title>
          <description>Strength of the association (odds ratio) of age, body mass index (BMI) z-score , and allergic status with response to Flovent. Allergic status is defined as a history of allergic disease (allergic rhinitis, hay fever, atopic dermatitis, eczema, food anaphylaxis, asthma, or positive skin prick tests). Response is defined as &lt;= 1 eosinophil/high power field in esophageal biopsies.</description>
          <population>Analysis population is restricted only to those that were given Flovent for the purpose of determining whether these specific variables are associated with response to drug</population>
          <units>Odds Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Odds Ratio for Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.907" lower_limit="0.779" upper_limit="1.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Odds Ratio for BMI Z-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.541" lower_limit="0.205" upper_limit="1.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Odds Ratio for Allergic Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.572" lower_limit="0.049" upper_limit="6.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EoE Score After 3 Months</title>
        <description>The gene expression profile is associated with an EoE score algorithm reflecting disease status and severity in a quantifiable number - called the EoE score, based on a core set of 77 diagnostic genes. The EoE score was calculated for Flovent responders and placebo. Higher scores indicate normalization of genes associated with inflammation and fibrosis (disease severity). Therefore higher scores mean a better outcome. The minimum score is zero. There is no maximum score.</description>
        <time_frame>3 months</time_frame>
        <population>Population includes only responders to Flovent and all participants finishing the study on Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Flovent 1760 mcg Responders</title>
            <description>Drug&#xD;
Flovent : 1760 mcg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>EoE Score After 3 Months</title>
          <description>The gene expression profile is associated with an EoE score algorithm reflecting disease status and severity in a quantifiable number - called the EoE score, based on a core set of 77 diagnostic genes. The EoE score was calculated for Flovent responders and placebo. Higher scores indicate normalization of genes associated with inflammation and fibrosis (disease severity). Therefore higher scores mean a better outcome. The minimum score is zero. There is no maximum score.</description>
          <population>Population includes only responders to Flovent and all participants finishing the study on Placebo.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382" spread="47"/>
                    <measurement group_id="O2" value="152" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Compliance With Therapy and Response to Flovent</title>
        <description>Odds ratio was determined to show the strength of the association between compliance with the drug therapy and response to the drug therapy</description>
        <time_frame>3 months</time_frame>
        <population>Analysis population is restricted only to those that were given Flovent for the purpose of determining whether compliance with therapy was associated with response to drug</population>
        <group_list>
          <group group_id="O1">
            <title>Flovent 1760 mcg</title>
            <description>Drug&#xD;
Flovent : 1760 mcg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Compliance With Therapy and Response to Flovent</title>
          <description>Odds ratio was determined to show the strength of the association between compliance with the drug therapy and response to the drug therapy</description>
          <population>Analysis population is restricted only to those that were given Flovent for the purpose of determining whether compliance with therapy was associated with response to drug</population>
          <units>Odds Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.037" lower_limit="0.988" upper_limit="1.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Abdominal Pain After Therapy</title>
        <description>Percent of participants responding that they experienced abdominal pain (i.e. they did not respond &quot;never&quot;) after therapy. Responses were dichotomized into &quot;Never&quot; and &quot;sometimes&quot;.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flovent 1760 mcg</title>
            <description>Drug&#xD;
Flovent : 1760 mcg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Abdominal Pain After Therapy</title>
          <description>Percent of participants responding that they experienced abdominal pain (i.e. they did not respond &quot;never&quot;) after therapy. Responses were dichotomized into &quot;Never&quot; and &quot;sometimes&quot;.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From consent to cessation of treatment which was approximately 4 months</time_frame>
      <desc>Adverse events were reported according to the MedDRA System Organ Class</desc>
      <group_list>
        <group group_id="E1">
          <title>Flovent 1760 mcg</title>
          <description>Drug&#xD;
Flovent : 1760 mcg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo : daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc E Rothenberg</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>513-636-7177</phone>
      <email>rothenberg@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

